WTG
KRYS icon

West Tower Group’s Krystal Biotech KRYS Stock Holding History

West Tower Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-431
Closed -$53.5K – 317
2023
Q4 		$53.5K Buy
431
+347
+413% +$38.5K 0.11% 155
2023
Q3 		$9.74K Buy
84
+48
+133% +$5.86K 0.01% 401
2023
Q2 		$4.23K Buy
+36
New +$3.68K ﹤0.01% 525

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

West Tower Group's KRYS Position: Q1 2024 in Review

West Tower Group sold out of Krystal Biotech (KRYS) in Q1 2024, closing a stake of 431 shares — an estimated $53.5K sold.

West Tower Group first reported a position in KRYS in Q2 2023 and held it in 3 quarters. The position peaked at $53.5K in Q4 2023. 234 funds tracked by Wall St. Rank hold KRYS as of Q1 2024.

  • West Tower Group reported no remaining Krystal Biotech position as of Q1 2024 after selling out during the quarter.
  • West Tower Group sold 431 Krystal Biotech shares in Q1 2024, an estimated $53.5K.
  • West Tower Group first reported a position in Krystal Biotech in Q2 2023 and held it in 3 quarters.
  • West Tower Group's Krystal Biotech position peaked at $53.5K in Q4 2023.
  • 234 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2024.

Based on West Tower Group's 13F filing for Q1 2024, filed 14 May 2024.